167832-26-0

Basic information

• Product Name: trans-3-AMino-1-Cbz-4-hydroxypiperidine
• Synonyms: trans-3-AMino-1-Cbz-4-hydroxypiperidine;trans-3-AMino-1-Cbz-4-hyd...;trans-Benzyl 3-amino-4-hydroxypiperidine-1-carboxylate
• CAS NO: 167832-26-0
• Molecular Formula: C13H18N2O3
• Molecular Weight: 250.29362
• Mol File: 167832-26-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: trans-3-AMino-1-Cbz-4-hydroxypiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: trans-3-AMino-1-Cbz-4-hydroxypiperidine(167832-26-0)
• EPA Substance Registry System: trans-3-AMino-1-Cbz-4-hydroxypiperidine(167832-26-0)

Safety Data

• Hazardous Substances Data: 167832-26-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Trans-3-AMino-1-Cbz-4-hydroxypiperidine is utilized as a key intermediate in the preparation of various medicinally important molecules. Its structural features make it a valuable component in the synthesis of drugs with different therapeutic applications.
Used in Antiviral Agents:
In the pharmaceutical industry, trans-3-AMino-1-Cbz-4-hydroxypiperidine is used as a building block for the development of antiviral agents. Its presence in the molecular structure of these drugs contributes to their antiviral properties, making it an essential component in the fight against viral infections.
Used in Antihypertensive Agents:
Trans-3-AMino-1-Cbz-4-hydroxypiperidine also plays a role in the synthesis of antihypertensive agents, which are medications used to treat high blood pressure. Its incorporation into these drugs aids in their ability to regulate blood pressure, thus contributing to the management of hypertension.
Used in Drug Development:
In the field of drug development, trans-3-AMino-1-Cbz-4-hydroxypiperidine is employed as a versatile compound for the creation of new pharmaceutical products. Its chemical properties allow for the exploration of various drug candidates, potentially leading to the discovery of novel therapeutic agents.

Upstream product

• 66207-08-7 3,4-epoxy-piperidine-1-carboxylic acid benzyl ester 
• 1624258-63-4 rac-benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 
• 66207-23-6 1-benzyloxycarbonyl-1,2,3,6-tetrahydropyridine 
• 1270498-29-7 (3R,4R)-benzyl 3-azido-4-hydroxypiperidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 
• 1174063-42-3 3-azido-4-hydroxypiperidine-1-carboxylic acid benzyl ester 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 694-05-3 1,2,3,6-tetrahydropyridine 
• 859854-67-4 trans-benzyl 3-((tert-butoxycarbonyl)amino)-4-hydroxypiperidine-1-carboxylate 
• 1052715-76-0 benzyl (3R,4R)-3-[(tert-butoxycarbonyl)amino]-4-hydroxypiperidine-1-carboxylate 
• 1624258-63-4 C₁₃H₁₅NO₃ 

Downstream Products

• 859854-67-4 3-tert-butoxycarbonylamino-4-hydroxypiperidine-1-carboxylic acid benzyl ester 
• 1052715-50-0 C₁₉H₂₈N₂O₇S 
• 1052715-53-3 C₁₉H₂₄N₂O₆ 
• 1052713-37-7 (3S,4S)-benzyl 3-(tert-butoxycarbonylamino)-4-(tert-butyldimethylsilyloxy)piperidine-1-carboxylate 
• 1620011-88-2 C₃₉H₅₄F₂N₆O₆SSi 
• 1052713-36-6 benzyl (3R,4R)-3-(tert-butoxycarbonylamino)-4-(tertbutyldimethylsilyloxy)piperidine-1-carboxylate 
• 1620015-15-7 C₃₉H₅₄F₂N₆O₆SSi 
• 1620011-89-3 (3R,4R)-5-amino-N-{4-[3,4-trans-3-amino-4-hydroxypiperidin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 
• 1052715-48-6 (3R,4R)-benzyl 3-(tert-butoxycarbonylamino)-4-(methylsulfonyloxy)-piperidine-1-carboxylate 
• 1052715-49-7 benzyl (3aR,7aS)-2-oxohexahydro[1,3]oxazolo[4,5-c]pyridine-5(4H)-carboxylate 
• 1052715-52-2 (3aR,7aS)-5-benzyl 3-tert-butyl 2-oxotetrahydro-oxazolo[4,5-c]pyridine-3,5(2H,6H)-dicarboxylate 
• 1620015-18-0 C₃₄H₃₈F₂N₆O₇S 
• 1620015-17-9 (3R,5S)-5-amino-N-{4-[3,4-cis-3-amino-4-hydroxypiperidin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 
• 1620012-04-5 C₃₈H₅₀F₂N₆O₆S₂Si 

Relevant articles and documents

Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators

We describe here the design, synthesis and characterization of a series of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as metabotropic glutamate receptor (mGluR) 5 negative allosteric modulators (NAMs). Optimization of the substituents led to the identifica

2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS

Compounds of formula (I): wherein; R1 is hydrogen or C1-6alkyl;R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy;R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl;R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6 alkyl;A is C—R5 or N;B is C—R6 or N;D is C—R7 or N;with the proviso that at least one of A, B, and D, is N;R5 is hydrogen or C1-6alkyl;R6 is hydrogen or C1-6alkyl;R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy;R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen;R9 is hydrogen or hydroxy;R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

BETA-LACTAMASE INHIBITORS

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS

The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

2 - (AZAINDOL- 2 -YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS

Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O-, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C-R5 or N; B is C-R6 or N; D is C-R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

Structure guided optimization, in vitro activity, and in vivo activity of pan-PIM kinase inhibitors

Proviral insertion of Moloney virus (PIM) 1, 2, and 3 kinases are serine/threonine kinases that normally function in survival and proliferation of hematopoietic cells. As high expression of PIM1, 2, and 3 is frequently observed in many human malignancies, including multiple myeloma, non-Hodgkins lymphoma, and myeloid leukemias, there is interest in determining whether selective PIM inhibition can improve outcomes of these human cancers. Herein, we describe our efforts toward this goal. The structure guided optimization of a singleton high throughput screening hit in which the potency against all three PIM isoforms was increased >10,000-fold to yield compounds with pan PIM Kis 10 pM, nanomolar cellular potency, and in vivo activity in an acute myeloid leukemia Pim-dependent tumor model is described.

BRUTON'S TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Heterocyclic Kinase Inhibitors

New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

INHIBITORS OF JAK

The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R′, X, X′, Y, Z1, Z2, and Z3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

CHEMICAL COMPOUNDS 251

The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.